Immunotherapy in the Context of Hematopoietic Stem Cell Transplantation: The Emerging Role of Natural Killer Cells and Mesenchymal Stromal Cells

Lankester, Arjan C.; Ball, Lynne M.; Lang, Peter; Handgretinger, Rupert

doi:10.1016/j.pcl.2009.12.001

Cited by 7 publications

(5 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Along the same line, haploidentical HSCT is considered of particular interest because of the reported association of strong alloreactive NK cell-mediated GvL responses observed in hematological malignancies [67,[82][83][84][85]. As reviewed by others [86], a KIR-ligand mismatch in the graft-versus-host direction in a donor and transplant recipient pair has been found in several studies to be predictive for a low risk of relapse [67,[82][83][84][85]. This is a form of anti-host NK cell alloreactivity that extends to the recipient tumor cell and that relies on the key principle of NK cell killing on the basis of missing-self.…”

Section: Allogeneic Hematopoietic Stem Cell Transplantation and The Gmentioning

confidence: 99%

“…Figure illustrates how tumor killing may occur according to these two mechanisms. Marked variability, however, has been reported in the predictive potential of these two models, and this has been ascribed to variation in disease and transplant conditions . In addition, inconsistency in clinical responses of alloreactive NK cells have been ascribed to the heterogeneity in NK cell subpopulations and the involvement of activating NK cell receptors .…”

Section: Allogeneic Hematopoietic Stem Cell Transplantation and The Gmentioning

confidence: 99%

See 1 more Smart Citation

The graft‐versus‐neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms

Willems

Waer

Billiau

2014

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Despite aggressive treatment, patients with high-risk neuroblastoma face high relapse rates and bleak prognoses. Increasing evidence that neuroblastoma cells are or can become immunogenic has stimulated research into novel therapies based on triggering or enhancing tumor immunity. Here we review clinical and experimental studies on this subject, the underlying immune mechanisms and perspectives for clinical application. Allogeneic hematopoietic stem cell transplantation has proven to be of substantial benefit in the treatment of certain leukemias through the generation of a graft-versus-leukemia-effect and has become of interest as a possible treatment for patients with solid tumors, including neuroblastoma.

show abstract

Section: Allogeneic Hematopoietic Stem Cell Transplantation and The Gmentioning

confidence: 99%

Section: Allogeneic Hematopoietic Stem Cell Transplantation and The Gmentioning

confidence: 99%

The graft‐versus‐neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms

Willems

Waer

Billiau

2014

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…41 HSCT from haploidentical, NK-alloreactive donors was also reported to lower the risk of relapse in children with ALL. 33,42,43 In addition to NK-cell alloreactivity, maternal donors (as opposed to any other donor-recipient family relationship) provided much better protection from leukemia relapse. The effect was independent of, and additive to, the beneficial effects of NK alloreactivity ( Figure 4C).…”

Section: How Mega-dose Transplants Overcome the Hla Barriermentioning

confidence: 99%

Haploidentical hematopoietic transplantation: current status and future perspectives

Reisner

Hagin

Martelli

2011

Blood

157

138

View full text Add to dashboard Cite

For patients with hematologic malignancies at high risk of relapse who do not have matched donors, a suitable alternative stem cell source is the HLAhaploidentical 2 or 3-loci mismatched family donor who is readily available for nearly all patients. Transplantation across the major HLA barrier is associated with strong T-cell alloreactions, which were originally manifested as a high incidence of severe GVHD and graft rejection. The present review shows how these obstacles to successful transplantation were overcome in the last 15 years, making full haplotypemismatched transplantation a clinical reality that provides similar outcomes to transplantation from matched unrelated donors. The review also discusses the advantages and drawbacks of current options for full haplotypemismatched transplantation and highlights innovative approaches for rebuilding immunity after transplantation and improving survival. (Blood. 2011; 118(23):6006-6017) IntroductionDespite advances in chemotherapy, allogeneic hematopoietic stem cell transplantation (HSCT) remains the best postremission therapy for patients with acute leukemia and unfavorable prognostic features at diagnosis, primary induction failure, or in second and third complete remission (CR). Even though HLAidentical siblings are the ideal source of hematopoietic stem cells (HSCs), only 25% of patients have such donors. Therefore, an alternative HSC source is needed for majority of patients. Alternative options include matched unrelated donors (MUDs), unrelated donor umbilical cord blood (UD-UCB), and full haplotype-mismatched related donor.Each alternative source has its own particular advantages and drawbacks. Suitable MUD are found for 60% to 80% of whites but only for 10% of ethnic minorities. 1 Using molecular probes improves tissue typing and lessens the risk of GVHD by very accurately matching unrelated donor-recipient pairs but reduces the probability of finding a suitable donor. Furthermore, as months can pass while identifying the donor and harvesting the HSCs, many acute leukemia patients relapse while awaiting transplantation.UD-UCB offers the advantages of a shorter search time than MUD and acceptance of 2-of 6-antigen mismatch. In adults, however, the great discrepancy between body weight and the number of HSC in a standard cord blood unit, particularly if a 2-antigen mismatch is involved, delays hematopoietic reconstitution and increases the risk of graft failure. This drawback was partially overcome using double cord blood units. 2 The advantages of transplantation from a full haplotypemismatched family member include: availability for almost all patients, choice of best donor from a panel of candidate family members, no undue delay in obtaining the graft and finally, easy access to donor-derived cellular therapies if required after transplantation.Major drawbacks are the very strong graft-versus-host and host-versus-graft alloresponses because of the high frequency of T cells that recognize major class I or II HLA disparities between donor and recipient. 3 ...

show abstract

“…Biological monitoring is pivotal in these studies and should involve evaluation of both soluble and cellular biomarkers, as well as histological analysis of GVHD-affected tissues [66]. …”

Section: Ebmtg/ibfm Gvhd Trials (In Steroid-refractory Gvhd)mentioning

confidence: 99%

Challenges and Opportunities for International Cooperative Studies in Pediatric Hematopoeitic Cell Transplantation: Priorities of the Westhafen Intercontinental Group

Schultz

Baker

Boelens

et al. 2013

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

More than 20% of allogeneic hematopoietic cell transplantations (HCTs) are performed in children and adolescents at a large number of relatively small centers. Unlike adults, at least one-third of HCTs in children are performed for rare, nonmalignant indications. Clinical trials to improve HCT outcomes in children have been limited by small numbers and these pediatric-specific features. The need for a larger number of pediatric HCT centers to participate in trials has led to the involvement of international collaborative groups. Representatives of the Pediatric Blood and Marrow Transplant Consortium, European Group for Blood and Marrow Transplantation’s Pediatric Working Group, International Berlin-Frankfurt-Munster (iBFm) Stem Cell Transplantation Committee, and Children’s Oncology Group’s Hematopoietic Stem Cell Transplantation Discipline Committee met on October 3, 2012, in Frankfurt, Germany to develop a consensus on the highest priorities in pediatric HCT. In addition, it explored the creation of an international consortium to develop studies focused on HCT in children and adolescents. This meeting led to the creation of an international HCT network, dubbed the Westhafen Intercontinental Group, to develop worldwide priorities and strategies to address pediatric HCT issues. This review outlines the priorities of need as identified by this consensus group.

show abstract

Immunotherapy in the Context of Hematopoietic Stem Cell Transplantation: The Emerging Role of Natural Killer Cells and Mesenchymal Stromal Cells

Cited by 7 publications

References 128 publications

The graft‐versus‐neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms

The graft‐versus‐neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms

Haploidentical hematopoietic transplantation: current status and future perspectives

Challenges and Opportunities for International Cooperative Studies in Pediatric Hematopoeitic Cell Transplantation: Priorities of the Westhafen Intercontinental Group

Contact Info

Product

Resources

About